Edesa Biotech, Inc. (EDSA) Form 424B5 — Aug 19, 2026
Edesa Biotech filed a preliminary prospectus supplement (Form 424B5) for an underwritten offering of common shares — or pre-funded warrants for certain investors — each sold together with an accompanying common share warrant, led by Guggenheim Securities as book-running manager. Pricing, share count and proceeds are left blank pending final terms; the stock's last reported sale was $5.71 on August 18, 2026. The common share warrants will be exercisable until the earlier of the 18-month anniversary of issuance and 30 days after the company announces Phase 2 vitiligo topline data for its EB06 anti-CXCL10 antibody.
Key figures
- Warrant term
- earlier of 18 months from issuance and 30 days after announcement of Phase 2 vitiligo topline data for EB06
- Lockup period days
- 90
- Options outstanding
- 378039
- Ards phase3 patients
- 278
- Warrant exercise fee
- 6% of gross proceeds from common share warrant exercises (FINRA 5110(g)(10))
- Aki subgroup patients
- 101
- Greenshoe window days
- 30
- Rsu shares underlying
- 1878201
- Atm remaining capacity
- $2,262,508 with H.C. Wainwright
- Net tangible book value
- $6.9 million, or $0.72 per common share (June 30, 2026)
- Last reported sale price
- $5.71 per share (August 18, 2026)
- Existing warrants outstanding
- 745349
- Pre funded warrant exercise price
- $0.0001 per share
- Vitiligo phase2 target enrollment
- 80
- Options weighted avg exercise price
- 24.7
- Series a1 preferred conversion shares
- 435414
- Series b1 preferred conversion shares
- 3833333
- Underwriter expense reimbursement cap
- $150,000
- Existing warrants weighted avg exercise price
- 15.62
Price after filing
Close on the filing date to close N calendar days later (from $5.75). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.